Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects

被引:52
作者
Greyling, A [1 ]
De Witt, C [1 ]
Oosthuizen, W [1 ]
Jerling, JC [1 ]
机构
[1] North West Univ, Sch Physiol Nutr & Consumer Sci, Potchefstroom, South Africa
关键词
policosanol; lipids; cholesterol; familial hypercholesterolaemia;
D O I
10.1079/BJN20061715
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Policosanol is a mixture of higher aliphatic primary alcohols that is extracted from purified sugar cane wax or a variety of other plant sources, and has been shown to have beneficial effects on serum lipid concentrations. The objective of this study was to investigate the effects of a policosanol supplement (Octa-60) on lipid profiles of hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Nineteen hypercholesterolaemic and familial hypercholesterolaemic subjects completed this randomised, placebo-controlled, double-blind study. The subjects received either a daily dose of 20 mg policosanol or placebo for 12 weeks. After a wash-out period of 4 weeks, the interventions were crossed over. Lipid levels were measured at baseline and at the end of each intervention period. No significant differences in total cholesterol and LDL-cholesterol from baseline to end or between policosanol and placebo were seen in the hypercholesterolaemic or familial hypercholesterolaemic groups. There were small reductions in total cholesterol and LDL-cholesterol from baseline to end in the hypercholesterolaemic group, but these changes did not differ significantly from the changes with the placebo, indicating that the observed decrease in cholesterol in the policosanol group was not due to the specific effect of policosanol treatment. The differences in response may be ascribed to the differences in composition of the higher aliphatic primary alcohols in the previously used products, compared with the local policosanol supplement. An intake of 20 mg/d policosanol for 12 weeks had no significant effect on serum lipid levels in hypercholesterolaemic and heterozygous familial hypercholesterolaemic patients when compared with placebo intake.
引用
收藏
页码:968 / 975
页数:8
相关论文
共 64 条
[11]   EFFICACY AND TOLERABILITY OF POLICOSANOL IN ELDERLY PATIENTS WITH TYPE-II HYPERCHOLESTEROLEMIA - A 12-MONTH STUDY [J].
CASTANO, G ;
CANETTI, M ;
MOREIRA, M ;
TULA, L ;
MAS, R ;
ILLNAIT, J ;
FERNANDEZ, L ;
FERNANDEZ, JC ;
DIAZ, E .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (08) :819-828
[12]  
Castaño G, 2002, INT J CLIN PHARM RES, V22, P89
[13]  
Castaño G, 1999, INT J CLIN PHARM RES, V19, P105
[14]   Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia [J].
Castaño, G ;
Mas, R ;
Fernández, L ;
Illnait, J ;
Mesa, M ;
Alvarez, E ;
Lezcay, M .
DRUGS & AGING, 2003, 20 (02) :153-163
[15]   Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk [J].
Castaño, G ;
Más, R ;
Fernández, JC ;
Illnait, J ;
Fernández, L ;
Alvarez, E .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2001, 56 (03) :M186-M192
[16]   Effects of policosanol on postmenopausal women with type II hypercholesterolemia [J].
Castaño, G ;
Más, R ;
Fernández, L ;
Fernández, JC ;
Illnait, J ;
López, LE ;
Alvarez, E .
GYNECOLOGICAL ENDOCRINOLOGY, 2000, 14 (03) :187-195
[17]  
Castaño G, 2002, INT J CLIN PHARM RES, V22, P55
[18]  
Castaño G, 2001, INT J CLIN PHARM RES, V21, P43
[19]   Effects of policosanol on borderline to mildly elevated serum total cholesterol levels:: A prospective, double-blind, placebo-controlled, parallel-group, comparative study [J].
Castaño, G ;
Más, R ;
Fernández, J ;
López, E ;
Illnait, J ;
Fernández, L ;
Mesa, M .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2003, 64 (08) :522-537
[20]   Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus [J].
Castaño, G ;
Fernández, L ;
Mas, R ;
Illnait, J ;
Mesa, M ;
Fernández, JC .
CLINICAL DRUG INVESTIGATION, 2003, 23 (10) :639-650